0000000001217008

AUTHOR

Jose M. Tau

showing 1 related works from this author

Exploratory study on the effects of biodegradable nanoparticles with drugs on malignant B cells and on a human/mouse model of Burkitt lymphoma.

2010

The aim of this study was to determine if Rituximab coated Biodegradable Nanoparticles (BNPs) loaded with Chlorambucil and Hydroxychloroquine could induce apoptosis of B-Chronic Lymphocytic Leukemia (B-CLL), MEC-1 and BJAB cells in vitro and evaluate their toxic and therapeutic effects on a Human/Mouse Model of Burkitt Lymphoma at an exploratory, proof of concept scale. We found that Rituximab-Chlorambucil-Hydroxychloroquine BNPs induce a decrease in cell viability of malignant B cells in a dose-dependent manner. The mediated cytotoxicity resulted from apoptosis, and was confirmed by monitoring the B-CLL cells after Annexin V/propidium iodide staining. Additional data revealed that these BN…

Pathologymedicine.medical_specialtyCell Survivalhuman/mouse model of Burkitt lymphoma.human lymphomamodel SCID mouseAntineoplastic Agentschemistry.chemical_compoundAntibodies Monoclonal Murine-DerivedMicerituximabimmune system diseasesAnnexinhemic and lymphatic diseasesnanoparticles; rituximab; human lymphoma; model SCID mouseTumor Cells CulturedMedicineAnimalsHumansPharmacology (medical)Propidium iodideGeneral Pharmacology Toxicology and PharmaceuticsCytotoxicityB-LymphocytesChlorambucilDose-Response Relationship Drugbusiness.industrymalignant B cellnanoparticleDrug SynergismGeneral MedicineBiodegradable nanoparticles with drugmedicine.diseaseBurkitt LymphomaLymphomaMice Inbred C57BLLeukemiaDisease Models AnimalDrug CombinationschemistryApoptosisMonoclonalCancer researchNanoparticlesChlorambucilbusinessRituximabmedicine.drugHydroxychloroquine
researchProduct